R. Quek

502 total citations
20 papers, 254 citations indexed

About

R. Quek is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, R. Quek has authored 20 papers receiving a total of 254 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in R. Quek's work include Sarcoma Diagnosis and Treatment (7 papers), Lymphoma Diagnosis and Treatment (5 papers) and Vascular Tumors and Angiosarcomas (3 papers). R. Quek is often cited by papers focused on Sarcoma Diagnosis and Treatment (7 papers), Lymphoma Diagnosis and Treatment (5 papers) and Vascular Tumors and Angiosarcomas (3 papers). R. Quek collaborates with scholars based in Singapore, United Kingdom and Japan. R. Quek's co-authors include M. Tao, Soon Thye Lim, Lay Cheng Lim, David Chee Eng Ng, Siew Wan Hee, Yao Tan, Joanne Ngeow, Yu Xuan Koo, Jae Heun Chung and Mohamad Farid and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and British Journal of Cancer.

In The Last Decade

R. Quek

18 papers receiving 250 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. Quek Singapore 4 191 125 65 65 59 20 254
Donato Mannina Italy 9 193 1.0× 76 0.6× 62 1.0× 80 1.2× 64 1.1× 24 292
Michaela Rancea Germany 5 236 1.2× 91 0.7× 79 1.2× 144 2.2× 30 0.5× 11 301
Ingrid Vášová Czechia 7 192 1.0× 78 0.6× 35 0.5× 153 2.4× 35 0.6× 35 293
Annalisa Gabriele Italy 8 255 1.3× 87 0.7× 58 0.9× 112 1.7× 37 0.6× 12 315
Jonas Karlén Sweden 8 244 1.3× 102 0.8× 88 1.4× 91 1.4× 48 0.8× 11 404
M. Tao Singapore 4 210 1.1× 134 1.1× 92 1.4× 130 2.0× 65 1.1× 19 358
Catherine Burton United Kingdom 7 147 0.8× 57 0.5× 27 0.4× 86 1.3× 39 0.7× 15 210
Karen Juul Mylam Denmark 9 404 2.1× 162 1.3× 136 2.1× 112 1.7× 164 2.8× 16 440
Sara Steffanoni Italy 7 176 0.9× 114 0.9× 26 0.4× 72 1.1× 24 0.4× 26 265
Kathrin Ruschke Germany 5 249 1.3× 82 0.7× 93 1.4× 79 1.2× 63 1.1× 7 320

Countries citing papers authored by R. Quek

Since Specialization
Citations

This map shows the geographic impact of R. Quek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Quek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Quek more than expected).

Fields of papers citing papers by R. Quek

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Quek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Quek. The network helps show where R. Quek may publish in the future.

Co-authorship network of co-authors of R. Quek

This figure shows the co-authorship network connecting the top 25 collaborators of R. Quek. A scholar is included among the top collaborators of R. Quek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Quek. R. Quek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Quek, R., Wen Yee Chay, Sze Huey Tan, et al.. (2017). Phase 2 clinical study of metronomic oral cyclophosphamide (MOC) in advanced sarcomas. Annals of Oncology. 28. x149–x150. 1 indexed citations
2.
Zhang, Alison Y., Ian Judson, Charlotte Benson, et al.. (2017). Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study. British Journal of Cancer. 117(3). 326–331. 18 indexed citations
3.
4.
Nagarajan, Chandramouli, Nicholas F. Grigoropoulos, S. Gopalakrishnan, et al.. (2017). VALIDATION OF THE CNS INTERNATIONAL PROGNOSTIC INDEX IN A LARGE ASIAN COHORT–DATA FROM THE SINGAPORE LYMPHOMA STUDY GROUP. Hematological Oncology. 35(S2). 197–198. 1 indexed citations
5.
Chan, Jason Yongsheng, Wei Lin Goh, Sathiyamoorthy Selvarajan, et al.. (2016). 504PD High neutrophil-lymphocyte ratio is an independent indicator of poor prognosis in high grade undifferentiated pleomorphic sarcoma. Annals of Oncology. 27. ix164–ix164. 1 indexed citations
6.
Poon, Eileen, et al.. (2016). 498PD_PR Prevalence and types of distress among Adult and Young Adolescent (AYA) newly diagnosed with cancer in Singapore. Annals of Oncology. 27. ix161–ix161. 1 indexed citations
7.
Goh, Wei Lin, et al.. (2016). 498PD_PR Prevalence and types of distress among Adult and Young Adolescent (AYA) newly diagnosed with cancer in Singapore. Annals of Oncology. 27(suppl_9). 1 indexed citations
8.
Goh, Wei Lin, Sze Huey Tan, Khee Chee Soo, et al.. (2016). Treatment and outcomes of melanoma in Asia: Results from National Cancer Centre Singapore. European Journal of Cancer. 60. e11–e12. 1 indexed citations
9.
Pang, Angela, Mark E. Puhaindran, Herbert H. Loong, et al.. (2016). 502O_PR Optimal first line systemic therapy in patients (pts) with metastatic angiosarcoma: A report from the Asian Sarcoma Consortium. Annals of Oncology. 27(suppl_9). 2 indexed citations
10.
Kang, Yoon‐Koo, Jianmin Xu, Yoshito Komatsu, et al.. (2013). Subgroup Analysis of Asian Patients in the Phase III Trial (GRID) of Regorafenib in Pretreated Metastatic GIST. Annals of Oncology. 24. ix6–ix6. 1 indexed citations
11.
12.
Chung, Jae Heun, et al.. (2011). Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Annals of Hematology. 90(7). 809–818. 98 indexed citations
13.
Quek, R., et al.. (2011). Do We Have the Right Prognostic Index for Diffuse Large B Cell Lymphoma (DLBCL) in the Era of Rituximab?. SHILAP Revista de lepidopterología. 20(1). 48–54. 1 indexed citations
14.
15.
Quek, R., Geoffrey I. Shapiro, James E. Butrynski, et al.. (2010). Combination mTOR+IGF-IR inhibition: Phase I trial of everolimus and CP-751871 in patients (pts) with advanced sarcomas and other solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 10002–10002. 8 indexed citations
16.
Tan, Soo‐Yong, et al.. (2010). Primary mediastinal large B-cell lymphoma: Optimal therapy and prognostic factors in 40 consecutive Asian patients.. Journal of Clinical Oncology. 28(15_suppl). 8074–8074.
17.
Ngeow, Joanne, R. Quek, David Chee Eng Ng, et al.. (2009). High SUV uptake on FDG–PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG–PET/CT staging in lymphoma. Annals of Oncology. 20(9). 1543–1547. 113 indexed citations
18.
Huynh, Hung, et al.. (2007). FOXO3a predicts for survival and its phosphorylated form is downregulated following mTOR or MEK inhibitor therapy in Hepatocellular Carcinoma. Journal of Clinical Oncology. 25(18_suppl). 4538–4538. 1 indexed citations
19.
Toh, Han Chong, et al.. (2007). Increased foxp3+ regulatory T cells predicts for superior relapse-free and overall survival in early stage hepatocelullar carcinoma. Journal of Clinical Oncology. 25(18_suppl). 4642–4642. 1 indexed citations
20.
Quek, R., Wan‐Teck Lim, Kian Fong Foo, Wen Hsin Koo, & Han Chong Toh. (2006). Capcitabine and oxaliplatin (XELOX) in the treatment of advanced gastric cancer. Journal of Clinical Oncology. 24(18_suppl). 14089–14089. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Donato Mannina Breakdown of academic impact, for papers by Michaela Rancea Breakdown of academic impact, for papers by Ingrid Vášová Breakdown of academic impact, for papers by Annalisa Gabriele Breakdown of academic impact, for papers by Jonas Karlén Breakdown of academic impact, for papers by M. Tao Breakdown of academic impact, for papers by Catherine Burton Breakdown of academic impact, for papers by Karen Juul Mylam Breakdown of academic impact, for papers by Sara Steffanoni Breakdown of academic impact, for papers by Kathrin Ruschke
Rankless by CCL
2026